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Platinum complex drugs such as cisplatin have been used as highly
successful chemotherapy drugs since the 1970s. We are interested in how the
ligands attached to cisplatin analogs influences their reactivity with biologically
relevant targets along with time and amount. For this study, reactions were
conducted to determine the reactivity between different platinum compounds and
the protein bovine serum albumin. Various platinum compounds with different
ligands were reacted in varying amounts with albumin in ammonium acetate
buffer for either 1 hour, 4 hours, or 24 hours. Each reaction was quenched after
the designated reaction time by dialysis and the platinum bound to the protein was
determined by use of ICP. LC-MS was used to find exact peptide residues
platinum complexes prefer to bind with but was found to be ineffective. Results
show that time has a more significant affect on binding over amount of platinum
present. In respect to changing the leaving or carrier ligands on the platinum
complex, these changes on the complex did not affect binding significantly with
bovine serum albumin. Triamine platinum complexes also seem to bind
significantly more than diamine platinum complexes along with anionic form
platinum complexes binding significantly better than the cationic form platinum
complexes.
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I. INTRODUCTION
A. Description and function of cancer
Throughout modern times, cancer has been a lead concern for researchers. It is
more prominent today than it was in the past, as seen with it being the second cause of
death in the United States. Cancer is characterized as a mutation where cells become
abnormal resulting in new cells being formed constantly while old cells do not go through
apoptosis to make room for the new. This results in the formation of a tumor from the
group of cells, which can be either benign (non-harmful) or malignant (harmful).
Malignant tumors are known to invade nearby tissue and spread throughout the body.
Upon spreading, the likelihood of a patient surviving diminishes the far the malignant
tumor spreads. Because of the risk of spreading, it is important on how soon it is
discovered for treatment purposes. Depending on the location and size, surgery can be
performed to remove the tumor but in most cases radiation and chemotherapy are used.
Chemotherapy uses various compounds that have a property that opposes cancer and kills
it. These compounds are classified as anticancer drugs or agents.
B. History and function of anticancer drugs
Chemotherapy was discovered in the 1940s during World War II but not as a
procedure for killing cancer at first. Studies at the time discovered that exposure to
mustard gas or mustard agents cause lower white blood cell counts in the subject.[1][2]
This would lead to further studies on the effectiveness of chemotherapy on rapidly
developing cells like those in cancer. In current times, chemotherapy is seen as the first
line of defense in various cancer treatments but its helpfulness in treatment is offset by
the various side effects caused by the various anticancer drugs along with built up
resistance to these drugs.
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Most metal complex anticancer drugs target and eradicate certain types of cancer.
Due to the positively charge metal atom centralized in the complex, metal complexes are
expected to bind to biomolecules in the body that are negatively charged which consists
of amino acids, nucleic acids, peptides, and proteins. This results in metal complex
adducts on the attached biomolecule causing cytotoxicity in the cell. Even those this
action is effective, metal complexes have a major drawback. This would be the fact metal
complexes cause bioaccumulation leading to unwanted side effects. The most common
metal complex anticancer drugs used today are those with platinum
C. Emergence of Platinum complex drugs
The first platinum complex approved for use as an anti-cancer reagent in the United
States was cisplatin. It was first synthesized by Michael Peyrone in 1845 but was not
known for its anticancer activity till 1961 when biophysicist Barnett Rosenberg found it
unexpectedly during an experiment where he was determining if cell division was
effected by electric currents.[3][4][5] When the FDA approved cisplatin for use as an
anticancer reagent in 1978, cisplatin was used to treat ovarian and testicular cancers
primarily but also cervical, head, neck, and non-small-cell lung cancers. The effectivity
and lack of selectivity make cisplatin a great anticancer reagent, it is not without its
shortcomings in the form of side effects.[6][7] These side effects are renal impairment,
otoxicity, neurotoxicity, and severe anemia. To overcome these effects, more platinum
anticancer reagents would be introduced in following generations.
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Figure 1.1: Structures for cisplatin, carboplatin, and oxaloplatin
The second generation focused on an improved toxicological profile to
minimize side effects by changing the leaving ligands. The best known platinum
anticancer reagent from this generation is carboplatin, [Pt(C6H6O4)(NH3)2], which
was approved by the FDA in 2003 for ovarian cancer treatment. The third
generation of platinum complex drugs were created to decrease cisplatin
resistance in tumors that have gained a resistance. This was done by changing the
carrier ligands. The only third generation platinum complex drug approved by the
FDA for treatment is oxaliplatin, which was approved in 2005 for colorectal
cancer treatment.
D. Mechanism of action
Cisplatin and other platinum anticancer reagents typically enter the body
by use of an I.V. into the bloodstream. Once in the bloodstream, the platinum
complex can enter the cell either by passive diffusion or active transport. For
cisplatin, passive diffusion can occur if there is a difference in chlorine
concentration across the cell membrane. As for active transport, cisplatin will use
CTR1, copper transporter I.
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The structure of CTR1 consists of 190 amino acids which are organized
into three transmembrane domains consisting of an N-terminal extracellular
domain that is rich in methionines and histidines, a large intracellular loop, and a
short intracellular C-terminal tail.[8][9] These three transmembrane domains form
a stable homotrimer, with a shape like an inverted cone, creating a central pore
that acts like a channel across the cell membrane. To transport cisplatin, CTR1 is
very energy-independent but can be affected by changes in temperature, pH, or
potassium, K+, concentration in and out of the cell.[10][11] At the top of the pore or
narrower part lies two methionine rings where both rings have three methionines
each and at the bottom of the pore lies a ring consisting of three cysteines.[12][13]
As for the transmembrane domains in the pore, transmembrane domain (TM) 2 is
found to line the pore while TM1 is in between TM2 and TM3 from the same
monomer. On the intracellular side of the membrane, contacts between subunits
are done via the interactions between TM2 and TM3 from monomers that are
adjacent to one another, while on the extracellular side of the membrane TM2
mediates every interaction between monomers making TM2 the single most
important contributor to the pore.[14] As for TM3, it is used for tight helical
packing where the GXXXG motif allows it to approach TM1 on its own
monomer.
With the passage of cisplatin through its pore, CTR1 undergoes
conformational changes. However, the methionine residues in the ring around the
extracellular entrance of the pore are in fact not static but a flexible structure.[15]
The short loop that connects the ring region to TM3 allows the status of the
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methionine rings at the extracellular entrance to be communicated to other parts
of the monomer and trimer effectively resulting in this region being a good
candidate to be used as a sort of switch for conformational change. At the
intracellular side of the pore for CTR1, the N-terminal domain plays the role of a
“gate” or “concentrator” for cisplatin, while Cys189 at the C-terminal on the
extracellular side functions in a way as to open and close the top of the pore along
with controlling CTR1’s multimerization.[16][17][18]
As cisplatin goes through the transmembrane domains in CTR1, His139 and
possibly other charged amino acids in these domain act as a way to delay or slow
down movement through the pore. Due to relative binding affinities, the Cterminal end of CTR1 can transfer cisplatin to exporters ATP7A and ATP7B.[19]
Now on the intracellular side of the cell membrane, cisplatin undergoes an
aquation reaction thereby losing its chlorine leaving ligands to create a more
reactive, cationic form of its complex. Once cationic, cisplatin will be transferred
into the nucleus where it will bind to DNA by guanine at the N7 position resulting
in the formation of a cisplatin-DNA adduct by a GG 1, 2 intrastrand crosslinks.[20]
By binding to DNA, cisplatin causes replication and transcription inhibition
resulting in cell cycle arrest and apoptosis or cell death.
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B

A

Figure 1.2: Diagrams of CTR1
A) CTR1 assembled on cell membrane. The methionine-rich regions in the Nterminus are in yellow.
B) Illustration of CTR1’s trimeric pore. This diagram shows the concept that
when assembling as a trimer, CTR1 uses rings of methionines, histidines, and
cysteines that are stack which are used for transchelation reactions that keeps the
movement of cisplatin through the pore of CTR1 regulated.
E. Platinum complexes protein binding
Similar to DNA, platinum complexes can bind to various proteins.[21][22]
This is due to the platinum atom in the complex having a variety of potential
donor atoms to bind to in amino acids. Platinum favors binding to sulfur donor
residues as a primary binding target. This can be seen due to the fact that cisplatin
likes to bind to methionine and cysteine residues due to them having sulfur
residues. Between these two amino acids, cisplatin prefers methionine due to its
thioether functional group over cysteine with a thiol functional group. This would
explain how cisplatin is capable of using CTR1 for active transport without
6

having a copper ion due to the two methionine rings at the extracellular opening
of CTR1 and a cysteine ring at the intracellular opening into the cell. If no sulfur
donor groups are present, cisplatin can bind to nitrogen atoms by their lone pairs
in the amino acid histidine, similar to guanine in DNA.
Seeing that cisplatin can bind to either methionine, cysteine, or histidine
makes it possible to predict which amino acid sequence residues on a given
protein it will create an adduct with. Simply reacting cisplatin with a protein can
give you a glimpse of its binding affinity and by following up reacting by doing a
digestion can result in the exact amino acid sequences it prefers. Factors that
should be considered when testing binding affinity is to determine if amount
present or time allowed to react effects binding between the platinum complex
and the protein along with changing the carrying or leaving ligands on the
platinum complex result in a different binding affinity.
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II. EXPERIMENTAL
A. Materials used
Trace metal grade nitric acid, acetic acid, and ammonium hydroxide were
purchased from Fisher. Ammonium acetate was purchased from Acros Organics.
Cisplatin, potassium tetrachloroplatinate (II), and
dichloro(ethylenediamine)platinum(II) were purchased from Sigma Aldrich.
Platinum solution used for ICP standards was purchased from Inorganic Ventures.
Dichloro(N, N, N’, N’-tetraethylenediethylenetriamine)platinum(II),
(ethylenediamine)oxalatoplatinum(II), (ethylenediamine)dinitratoplatinum(II),
(N,N,N',N'-tetramethylethylenediamine)dinitritoplatinum II),
(diethylenetriamine)nitratoplatinum(II), chloro(diethylenetriamine)platinum(II),
and chloro(N, N-diethyldiethylenetriamine)platinum(II) were synthesized in
previous work. Deionized water was used in buffer preparation and dialysis of
sample.
B. Preparation of buffer
100 mM ammonium acetate buffer was made by mixing 771 mg of
ammonium acetate in 100 mL of water. Once mixed and the ammonium acetate
was completely dissolved, the solutions were brought to a pH of 8 by adding
small increments of ammonium hydroxide and acetic acid to adjust.
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C. Liquid Chromatography- Mass Spectroscopy (LC-MS)
1. Sample preparation
Samples were prepared by adding 5 mg of bovine serum albumin into a
vial and diluting with 10 mL of ammonium acetate buffer at pH 8. Once
dissolved, 1 mg of trypsin was added to each vial and the vial was inverted a
couple times to ensure trypsin was dissolving and the solution was homogenous.
Once done, samples were place in an incubator at 37 °C overnight. Samples
containing cisplatin were prepared similarly except 5 mg of cisplatin was added
into the sample before trypsin was added.[23]
2. Method used
20-µL aliquots of each sample were injected into a Varian Ion Trap 500
MS with two Varian 212 HPLC pumps at a constant flow rate of 0.2 mL/min.
Samples were run with mobile phase A being 0.1% formic acid in water and
mobile phase B being acetonitrile. A gradient was made by using 95% A and 5%
B at time zero, 95% A and 5% B at 5 minutes, 50% A and 50% B at 50 minutes,
10% A and 90% B at 55 minutes, 10% A and 90% B at 60 minutes, 95% A and
5% B at 62 minutes, and 95% A and 5% B at 70 minutes.[24]
D. Inductively Coupled Plasma Spectroscopy (ICP)
1. Sample preparation
Samples were prepared by dissolving 1 mg, 5 mg, or 10 mg of platinum complex
in 4 mL of 100 mM ammonium acetate buffer at a pH 8. 1 mg of bovine serum
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albumin was dissolved in 1 mL of buffer which was follow by adding the bovine
serum albumin solution to the platinum complex solution. After the addition,
samples were inverted carefully a few times to achieve homogeneity. Samples
were then allowed to react for either one hour, four hours, or twenty-four hour
intervals. To quench the sample at the desired end time, samples were put in
dialysis tubing and underwent dialysis twice for 10 minutes each in two different
beakers containing 500 mL of deionized water.
2. Method used
Standards for the calibration curve were made from trace grade platinum
in concentrations of 1, 5, 10, 25, and 100 ppm. Data were collected on a
ThermoScientific ICAP 6500 ICP-OES utilizing an argon plasma torch.
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III. RESULTS
A. LC-MS spectra
LC-MS scans were performed on samples with and without cisplatin in
them. (Figures 3.1 and 3.2) Since the amino acids that cisplatin prefer to bind to
on a protein are known along with the amino acid sequence residues from the
digestion of bovine serum albumin by trypsin, this method was designed to show
the exact binding sites on bovine serum albumin. On the spectra for the sample
without cisplatin, data was compared to the known residues for bovine serum
albumin-trypsin on EXPASY.

Figure 3.1: LC-MS spectra for bovine serum albumin-trypsin digestion
For both spectra, each had three major peaks past the thirty-five minute
mark of the run. The middle peak of these three on both is thought to be a
“cleaning” peak due to the rapid change in the concentration gradient around that
time interval. No usable data was found on this peak. The first and third peak for
both showed a few of the expected amino acid sequence residues but were at too
11

low of a value to be significant. The results acquired were not believed to
accurately portray the binding affinity between cisplatin and bovine serum
albumin so ICP was used to make sure of the binding affinity.

Figure 3.2: LC-MS spectra for cisplatin binding bovine serum albumin-trypsin
digestion.
B. ICP
1. Cisplatin
Since cisplatin was known to bind to proteins, it was used as a standard to
determine different factors that might affect binding affinity. To determine if
amount present would affect binding, cisplatin samples had either 1 mg, 5 mg, or
10 mg of cisplatin added in. time was tested for its effects at the same time in
intervals of one hour, four hours, and twenty-four hours. To ensure our results
were accurate for the sample, two different wavecounts, Pt2036 and Pt2245, were
used and compared. The results for Pt2036 can be seen in Table 3.1 and Figure
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3.3 while the results for Pt2245 are in Table 3.2 and Figure 3.4. Two trials were
run at each wavecount to ensure reproducibility.

Amount of Platinum Bound (μg)

Pt2036
Compound

Cisplatin

Mass
(mg)

Time
(Hr)
1

1 mg

4

79.73731 94.05496 86.89614 10.12411

24

597.1877 154.7203

1

105.6215 113.7136 109.6676 5.722009

4

108.5961 230.1614 169.3788 85.95965

24

713.2096 831.6078 772.4087 83.72011

1

40.79506 275.1715 157.9833 165.7292

4

429.0812 404.9951 417.0381 17.03144

24

759.3677 612.4582 685.9129 103.8807

5 mg

10 mg

Trial 1

Trial 2

79.23731

Average

S.D.

66.8059 73.02161 8.790333
375.954 312.8717

Table 3.3: ICP data for cisplatin using PT2036

μg of Platinum Bound

Pt2036
900
800
700
600
500
400
300
200
100
0
1

4

24

1

4

1 mg

24

1

4

5 mg

24

10 mg

Sample (hours reacted)
1 mg 1

1 mg 4

1 mg 24

5 mg 1

5 mg 4

5 mg 24

10 mg 1

10 mg 4

Figure 3.3: ICP data for cisplatin using Pt2036.
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10 mg 24

By looking at the data, time affects binding of cisplatin more than amount
present. The binding affinity for cisplatin to bovine serum albumin seem to
increase quickly overtime resulting in samples that went for twenty-four hours
having higher amounts of binding than at lower time intervals. Size only
marginally increased the amount of binding suggesting that there might be a limit
to how much can bind to a protein at a given time.
Amount of Platinum Bound (μg)

Pt2245
Compound

Cisplatin

Mass
(mg)

Time
(Hr)
1

1 mg

4

5 mg

10 mg

Trial 1

85.93911982

Trial 2

Average

69.0387 77.48891

S.D.

11.9504

24

85.93911982 96.94032 91.43972 7.77902
665.6216358 160.4459 413.0338 357.2132

1

114.8839962 118.3412 116.6126 2.444587

4

118.6220345 239.0319 178.8269

24
1

798.5711972 881.8984 840.2348 58.92126
848.5363088 287.0966 567.8165 396.9978

4

44.04817085 422.6394 233.3438 267.7044

24

476.3522976 645.4197

560.886 119.5487

Table 3.2: ICP data for cisplatin using PT2245.
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85.1426

Pt2245
μg of Platinum Bound

1200
1000
800
600
400
200
0
1

4

24

1

4

1 mg

24

1

4

5 mg

24

10 mg

Sample (hours reacted)
1 mg 1

1 mg 4

1 mg 24

5 mg 1

5 mg 4

5 mg 24

10 mg 1

10 mg 4

10 mg 24

Figure 3.4: ICP data for cisplatin using Pt2245
Comparing Pt2245 to Pt2036, the results are similar showing time being the major
factor like before. Due to Pt2036 and Pt2245 having fairly similar results, the
other platinum complexes tested by the ICP will only show results for Pt2036.
2. Leaving ligand changes
The next aspect to consider for effects on binding is the leaving ligands present.
As said previously, the second generation of platinum drugs focused on obtaining
a reduced toxicological profile from cisplatin which was done by changing the
leaving ligands. To test this part, platinum complexes utilizing the same carrier
ligands (ethylenediamine) but with different leaving ligands. Complexes used for
this part were (ethylenediamine)oxalatoplatinum (II) (Pt(en)(ox)),
(ethylenediamine)dinitratoplatinum (II) (Pt(en)(NO3)2), and
dichloro(ethylenediamine)platinum (II) (Pt(en)Cl2). (Table 3.3 and Figure 3.6)
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Figure 3.5: Structures for Pt(en)(ox), Pt(en)(NO3)2 and Pt(en)Cl2

Compound

Pt(en)(ox)

Mass
(mg)
1 mg

Time
(Hr)
1
4
24
1

Pt(en)(NO3)2

1 mg

4
24
1

1 mg

Pt(en)Cl2
5 mg

4
24
1
4
24

Amount of Platinum Bound (μg)
Trial 1
Trial 2
Average
S.D.

11.73031 4.005668 7.867991 5.462149
13.28197 13.50256 13.39226 0.155979
47.20905 89.34631 68.27768 29.79554
17.84189
17.84189
28.54221
28.54221
64.65849
64.65849
21.87854
21.87854
46.01301
46.01301
46.10912
46.10912
72.63568
72.63568
89.33758
89.33758
239.7936
239.7936

Table 3.3: ICP data for Pt(en)(ox), Pt(en)(NO3)2, and Pt(en)Cl2
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300

μg of Platinum Bound

250
200
150
100
50
0
1

4

24

1

4

24

1 mg

1 mg

Pt(en)(ox)

Pt(en)(NO3)2

1

4

24

1

1 mg

4

24

5 mg
Pt(en)Cl2

Sample (Hour Reacted)

Figure 3.6: ICP data for Pt(en)(ox), Pt(en)(NO3)2, and Pt(en)Cl2
Looking at the results, it seems that changing leaving ligands did not
significantly affect binding. The complex with the seemingly better binding looks
to be Pt(en)(NO3)2 with its nitro leaving ligands resulting in slightly higher
binding. Pt(en)(NO3)2, Pt(en)Cl2, and Pt(en)(ox) seem to bind almost the same
even with having different leaving ligands.
3. Carrier ligand changes
Another aspect tested was the effects on bind affinity by changing the carrier
ligand. As said previously, the third generation of platinum complex drugs
involved changing the carrier ligands to lower the resistance in cisplatin resistance
cells. Since the nitrate leaving ligand show to be slightly better, platinum
complexes were used having this ligand. Platinum complexes used for this part

17

were Pt(en)(NO3)2 and (N,N,N',N'-tetramethylethylenediamine)dinitratoplatinum
(II) (Pt(Me4en)(NO3)2). (Table 3.4 and Figure 3.8)

Figure 3.7: Structure of Pt(Me4en)(NO3)2.

Compound

Pt(en)(NO3)2

Pt(Me4en)(NO3)2

Mass (mg)

Time (Hr)

Amount of Platinum
Bound (μg)

1

17.84188719

4

28.54221396

24

64.65848658

1

30.49646526

4

45.32955298

24

80.06823861

1 mg

1 mg

Table 3.4: ICP data for Pt(en)(NO3)2 and Pt(Me4en)(NO3)2.
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μg of Platinum Bound

90
80
70
60
50
40
30
20
10
0
1

4

24

1

4

1 mg

24

1 mg

Pt(en)(NO3)2

Pt(Me4en)(NO3)2

Sample (Hours reacted)

Figure 3.8: ICP data for Pt(en)(NO3)2 and Pt(Me4en)(NO3)2.
Like with the leaving ligands, carrier ligands do not significantly affect
binding. The difference between these two leaving groups is marginal. The better
binding came from Pt(Me4en)(NO3)2 which was surprising due to previous work
showing the complex having a lack of binding with proteins.
4. Triamine platinum complexes
Since most platinum complexes tested in the first part have carrier ligands
containing ethylenediamine, we next studied diethylenetriamine complexes to see
how triamine complexes bond to protein. Complexes used to test were chloro(N,
N, N’, N’-tetraethyldiethylenetriamine)platinum (II) (Pt(Et4dien)Cl),
(diethylenetriamine)nitratoplatinum (II) (Pt(dien)(NO3)) (Table 3.5 and Figure
3.10), chloro(diethylenetriamine)platinum (II) (Pt(dien)Cl) and chloro(N, Ndiethyldiethylenetriamine)platinum (II) (Pt(Et2dien)Cl). (Table 3.6 and Figure
3.11)
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Figure 3.10: Structures for Pt(Et2dien)Cl, Pt(Et4dien)Cl, Pt(dien)(NO3), and
Pt(dien)Cl
Amount of Platinum Bound (g)
Compound

Pt(Et4dien)Cl

Mass
(mg)

Time
(Hr)
1

1 mg

4
24
1

Pt(dien)(NO3)

1 mg

4
24

Trial 1
29.93895
69.2495
116.5086
32.31486
155.9487
289.4318

Trial 2
64.23352
81.55121
83.3358
12.82013
30.14067
228.259

Average
47.08624
75.40036
99.92218
22.56749
93.04469
258.8454

Table 3.5: ICP data for Pt(dien)Cl and Pt(dien)(NO3)
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S.D.
24.24993
8.698623
23.45668
13.78486
88.95972
43.2557
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350
300
250
200
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50
0
1

4

24

1

4

1 mg

1 mg

Pt(Et4dien)Cl

Pt(dien)(NO3)

24

Sample (Hour reacted)

Figure 3.10: ICP data for Pt(dien)Cl and Pt(dien)(NO3)
Amount of Platinum Bound (g)
Compound

Pt(dien)Cl

Mass
(mg)

1 mg

Time
(Hr)
1
4
24
1

Pt(Et2dien)Cl

1 mg

4

Trial 1

Trial 2

Average

S.D.

57.83072

30.48331

44.15702

19.33754

66.85919

84.96335

75.91127

12.80158

72.77737

231.2571

152.0172

112.0621

6.381317

3.943583

5.16245

1.723739

6.548355

3.981021

5.264688

1.815379

6.645

3.992541

5.318771

1.875572

24

Table 3.6: ICP data for Pt(dien)Cl and Pt(Et2dien)Cl
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μg of Platinum Bound

300
250
200
150
100
50
0
1

4

24

1

4

1 mg

24

1 mg

Pt(dien)Cl

Pt(Et2dien)Cl

Sample (Hour reacted)
Pt(dien)Cl 1 mg 1

Pt(dien)Cl 1 mg 4

Pt(dien)Cl 1 mg 24

Pt(Et2dien)Cl 1 mg 1

Pt(Et2dien)Cl 1 mg 4

Pt(Et2dien)Cl 1 mg 24

Figure 3.11: ICP data for Pt(dien)Cl and Pt(Et2dien)Cl
By looking at the data, diethylenetriamine platinum complexes did in fact
bind to bovine serum albumin. The amount of binding for these complexes look
to be higher than what it was for ethylenediamine complexes. The only concern
here is that even though the rest of the complexes did bind, Pt(Et2dien)Cl did not
bind much at all if any. This brings question as to why this complex could not
bind.
5. Potassium tetrachloroplatinate (II)
Since most platinum complexes that bind to proteins are cationic in nature,
a anionic platinum complex was checked to see if the change in charge on the
complex would result in binding or lack of. Potassium tetrachloroplatinate (II)
(K2PtCl4) was used to test this. (Table 3.7 and Figure 3.13)
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Figure 3.12: Structure for K2PtCl4.
Amount of Platinum Bound (μg)
Compound

Mass
(mg)

Time
(Hr)
1

1 mg

K2PtCl4
5 mg

Trial 1

Trial 2

Average

S.D.

103.9571 153.5008 128.7289 35.03269

4

171.6618 170.4922

24

256.5596 249.8333 253.1964 4.756214

1

180.3224 194.5393 187.4309 10.05283

4

234.5609 212.8266 223.6937 15.36845

24

245.4534 483.2487

171.077 0.827018

364.351 168.1466

Table 3.7: ICP data for K2PtCl4.
600
500

Axis Title

400
300
200
100
0
1

4

24

1

4

1 mg
1 mg 1

1 mg 4

5 mg

Sample (Hours Reacted)

1 mg 24

5 mg 1

5 mg 4

Figure 3.13: ICP data for K2PtCl4.
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5 mg 24

24

Based on the results, K2PtCl4 seems to bind significantly with bovine
serum albumin. These results are surprising due to the fact that the anionic
complex form K2PtCl4 has would seem to prohibit binding. K2PtCl4 is known to
be slow to react with individual amino acids.
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IV. DISCUSSION
It seems that the method used for the LC-MS is ineffective due to the main
problem being the failure to identify peaks in absence of platinum. The results
obtained did not illustrate what truly was happening. The purpose for the LC-MS
analysis was to set up a method that would be able to tell what amino acid
sequence residues different platinum complexes prefer to bind with to better
understand protein binding. Due to the method being ineffective, changes will
need to be made to accurately test different platinum complexes’ binding affinity
with proteins.
When switching to ICP, the purpose of this study was to see what affects
the binding affinity between platinum complex and protein. We tested the
amount of platinum, time, carrier ligands, leaving ligands, and anionic forms to
see how each aspect affected binding. In regards to the amount of platinum
present, it seems that there is saturation of binding to the protein. This would
explain why time seemed to have the greater effect on binding. Over time, more
complex was shown to bind resulting in better binding happening at the twentyfour hour mark over the one hour mark.
With respect to the leaving ligands, the result of changing the ligands did
not change binding significantly. This could mean that by changing the leaving
ligands, toxicity would be altered, depending on the ligand change, but binding
would be the same or lower just like in second generation platinum drugs. As for
carrier ligands, the change did not affect binding significantly at all. This could
mean changing either the leaving ligands or the carrier ligands does not in fact
25

affect binding but focus more at changing the properties of the platinum complex
to ensure better anticancer reagents for chemotherapy.
We noticed with the diethylenetriamine platinum complexes that they did,
in fact, bind better than ethylenediamine complexes. It would seem that by
changing the carrier ligand from ethylenediamine to diethylenetriamine results in
better binding along with the possibility of improving the effectiveness in cells
with platinum complex resistances. The surprise factor of these complexes was
the fact that Pt(Et2dien)Cl did not bind relatively at all which warrants
investigating.
It was surprising that K2PtCl4 did bind given its anionic form. Since most
platinum complexes bind due to being cationic form, it raises questions how an
anionic form complex did bind. What possibly could have happen is a noncovalent interaction between K2PtCl4 and bovine serum albumin. Either way, this
warrants investigating. Future work would involve revising the method for the
LC-MS to ensure the desired results are achieved along with further studying of
protein binding affinity of platinum complexes but with different proteins.
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VI. ABBREVIATIONS

chloro(diethylenetriamine)platinum (II)………………………….……..Pt(dien)Cl
chloro(N, N-diethyldiethylenetriamine)platinum (II)…………...…...Pt(Et2dien)Cl
chloro(N, N, N’, N’-tetraethyldiethylenetriamine)platinum (II)…….Pt(Et4dien)Cl
(ethylenediamine)dinitratoplatinum (II)……………………….…….Pt(en)(NO3)2
(ethylenediamine)oxalatoplatinum (II)…………………………………..Pt(en)(ox)
dichloro(ethylenediamine)platinum (II)…………………………………..Pt(en)Cl2
diethylenetriamine)nitratoplatinum (II)………………………………...Pt(dien)(NO3)
Inductively Coupled Plasma Spectroscopy………………………………………...….ICP
Liquid Chromatography-Mass Spectroscopy…………………………………...…LC/MS

Potassium tetrachloroplatinate (II)…………………………………………K2PtCl4
(N,N,N',N'-tetramethylethylenediamine)dinitratoplatinum (II)….Pt(Me4en)(NO3)2
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